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Poster Session I S203(MM) and lymphoma (L) undergoing first SCM that used G (10
mcg/kg without dose escalation) and non-mobilizers had a maxi-
mum of 4 days of P.
Results: Among CY +G pts, 141 (61%) were males; 121 (50%) had
MM, 115 (48%) had L (5-other diagnoses); 61 (25%) pts. had prior
radiation. PCOwas seen in 48 (20%) pts., 23% ofMM and 15.7% of
L pts. Mean total cost of CY +G SCM was $10,732 (range, 6988-
30827). PCO was associated with a lower cost than non-PCO in
the overall group, (mean, $10,371 vs. $12,870, P5 0.001), in MM
pts. (mean, $10,511 vs. $12,152, P5 0.026), and in L pts (mean,
$10,133 vs. $13,627, P5 0.006). Assuming a similar distribution of
PCO in 100 pt. with MM and L, the projected per pt cost of SCM
would be $11,774 and $13,067 (mean, $12,421) with CY +G. Pro-
jected costs of SCM using P +G for 100 pts. with MM and L were
$12,852 and $8986 (mean, $10,919).
Conclusion: SCM with CY +G was associated with a lower rate of
PCO and higher cost than P +G. This comparision is limited by dif-
ferent sources of patient data, only the CY +G data was ‘‘real world’’,
and only product-related costs were examined. This study represents
an important initial step towards informing cancer management
based on a profile of outcomes that compare relevant therapeutic al-
ternatives.122
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Plerixafor plus G-CSF has been shown to mobilize more
CD34+ cells than G-CSF alone for autologous hematopoietic
stem cell transplant (HSCT). However, many centers use chemo-
therapy (chemo) followed by G-CSF to mobilize CD34+ cells
prior to HSCT. We performed a retrospective study of pts
who participated in the expanded access program (EAP) of pler-
ixafor/G-CSF for upfront mobilization of CD34+ cells, and com-
pared outcomes to matched historical controls mobilized with
chemo/G-CSF at two centers that participated in the study. Con-
trol pts were matched for age, sex, disease stage, and number of
prior therapies. Control pts received cyclophosphamide 3-5 gm/
m2 followed by daily G-CSF. Study pts received G-CSF 10
mcg/kg daily for 5 days and plerixafor 0.24 mg/kg was given
on the evening of day 4, twelve hours before apheresis on day
5. Mobilization costs were considered to be the costs of medical
procedures, resource utilization and medications. Median national
CMS reimbursement rates were used to evaluate the costs of pro-
cedures, hospitalization, provider visits, apheresis, CD34+ cell
processing and cryopreservation. Average sale price was used
for G-CSF, plerixafor, cyclophosphamide, mesna, antiemetics
and antimicrobials. A total of 34 patients from EAP and 34
matched controls were studied. Comparison of the number of
doses of G-CSF, number of apheresis, total CD34+ cells col-
lected, and cost is given in the table. Two pts in the control
group were hospitalized for neutropenic fever during the mobili-
zation period after receiving chemo. Apheresis started on the
scheduled day in 27 (79%) study pts and in 18 (53%) control
pts (p5 0.021). Unplanned starts of apheresis resulted in 17
(50%) control pts undergoing weekend apheresis. Study pts re-
ceived a median of 1 dose of plerixafor (median 16.9 mg), and
the average sale price for plerixafor in this analysis was $6,250
per 24 mg/vial. All pts proceeded to HSCT with no difference
in outcomes. In conclusion, plerixafor/G-CSF compared to
chemo/G-CSF for upfront mobilization of CD34+ cells resulted
in similar number of cells collected, cost of mobilization, and
clinical outcomes. However, plerixafor/G-CSF mobilization re-
sulted in more predictable days of collection, no weekend apher-esis procedures, and no unscheduled hospital admissions. Higher
acquisition cost of plerixafor was offset by less G-CSF use and
less resource utilization compared to cyclophosphamide based
mobilization.
Cost and Resource Comparison
All values median(range) Plerixafor/GCSF Chemo/GCSF p valueG-CSF dose 780ug (600-1440) 900ug (480-1260) 0.9No. G-CSF doses 5 (4-8) 10 (6-17) 0.0001Apheresis days 1 (1-4) 1 (1-4) 0.33Total CD34 cells
(million/kg)11.1 (3.5-37.9) 11.2 (2.1-69.3) 0.86Un-scheduled
hospital days0 2 0.0001Weekend
apheresis0 17 (50%) 0.0001Total Mobilization
Cost$18,817
(12,467-53,799)$18,893
(10,196-35,088)0.35123
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Introduction: High-dose melphalan and autologous HSC trans-
plantation produces the highest remission rate for patients (pts)
with amyloidosis. HSC mobilization/collection is challenging in
these patients, particularly those with cardiac involvement with re-
ported increased morbidity and even mortality. Thus, agents that
can mobilize stem cells safely, efficiently and effectively would be
beneficial in these patients. This retrospective analysis evaluated
the efficacy and safety of plerixafor + G-CSF (P +G) remobilization
in amyloidosis pts.
Methods: Pts with amyloidosis unable to collect $2106 CD34+
cells/kg in prior attempts were remobilized with P +G in a compas-
sionate use program (CUP). G-CSF (10 mg/kg SC) was given every
morning for 5 days. Plerixafor (0.24 mg/kg SC) was given in the
evening on Day 4,11 hours prior to apheresis the next day. Plerix-
afor, G-CSF and apheresis were repeated daily until pts collected
$2106 cells/kg.
Results:Of 1011 pts in the plerixafor CUP database, 11 pts were re-
ported to have amyloidosis. In prior mobilization attempts, 3 pts col-
lected 0.8, 0.17 and 0.9106 CD34+ cells/kg and in 8 pts, collection
was not attempted due to low circulating peripheral blood CD34+
cell numbers. Remobilization with P +G resulted in a median yield
of 6.6106 cells/kg; 10/11 pts collected the minimum target of
2106 cells/kg and 7/11 pts reached the optimal target of $5106
cells/kg with the majority (10/11) collecting the minimum cell
dose in 1 or 2 apheresis days. Ten pts went to transplant; median
time to platelet and neutrophil engraftment was 19 and 14 days, re-
spectively. Drug-related adverse events were experienced by 5 pts
during mobilization and collection and included injection site reac-
tions (5), nausea (2), diarrhea (2), headache (1), hyperuricemia (1),
hypokalemia (1), paraesthesias (1) and QT prolongation on electro-
cardiogram (1). The patient with the prolongedQT interval had car-
diac amyloidosis and hypokalaemia. This patient died approximately
1 month after mobilization and collection, of cardiac arrest not re-
lated to plerixafor.
Conclusion: These results provide preliminary evidence that P +G
can safely and effectively remobilize HSC in amyloidosis pts who
